Financial Performance - Net profit attributable to shareholders was CNY -372,663,728.15, compared to a profit of CNY 4,257,068.34 in the same period last year, representing a significant decline[16] - Operating revenue for the first nine months was CNY 7,649,073,314.94, down 9.63% year-on-year[16] - The basic earnings per share were CNY -0.13, compared to CNY 0.0017 in the same period last year[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -441,417,462.70, a decrease of 1,238.97% year-on-year[16] - The company reported a net loss attributable to shareholders of ¥372,663,728.15 for the year-to-date period, with a forecast of continued negative net profit through the next reporting period[26] - Total operating revenue for Q3 2020 was approximately ¥2.84 billion, a decrease of 3.7% compared to ¥2.95 billion in Q3 2019[45] - Net profit for the first three quarters of 2020 was a loss of approximately ¥252.29 million, compared to a profit of ¥161.46 million in the same period of 2019[48] - The net profit for Q3 2020 was a loss of approximately ¥114.87 million, compared to a loss of ¥104.92 million in Q3 2019, indicating a worsening performance[58] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,631,739,004.77, a decrease of 6.96% compared to the end of the previous year[16] - As of September 30, 2020, the company's total assets amounted to approximately ¥11.63 billion, a decrease from ¥12.50 billion as of December 31, 2019, reflecting a decline of about 6.95%[37] - The company's current assets totaled approximately ¥7.49 billion, showing an increase from ¥7.31 billion year-over-year, representing a growth of about 2.54%[37] - Total liabilities increased to approximately ¥6.93 billion from ¥6.56 billion, reflecting a rise of about 5.67%[39] - The company's equity attributable to shareholders decreased to approximately ¥4.19 billion from ¥5.46 billion, a decline of about 23.23%[39] - Total liabilities reached approximately ¥5.24 billion from ¥4.29 billion year-over-year[45] - The company's total equity decreased to approximately ¥2.15 billion from ¥3.63 billion year-over-year, reflecting a decline in retained earnings[45] Cash Flow - The net cash flow from operating activities improved to CNY -72,943,528.85, a 51.03% increase compared to CNY -148,960,490.16 in the previous year[16] - Net cash flow from operating activities improved by 51.03% to -¥72,943,528.85 from -¥148,960,490.16, mainly due to increased collections from accounts receivable[24] - Net cash flow from investing activities improved by 95.29% to -¥63,888,776.27 from -¥1,357,420,880.64, primarily due to the completion of GNC convertible preferred stock subscription in the previous period[24] - Net cash flow from financing activities surged by 739.77% to ¥703,247,644.11 from ¥83,743,205.18, mainly due to new loans obtained[24] - Cash inflow from operating activities totaled ¥8,580,795,005.33, slightly up from ¥8,509,000,187.23 year-on-year[62] - Cash outflow for operating activities was ¥8,653,738,534.18, compared to ¥8,657,960,677.39 in the previous year[62] - The company reported a net cash increase of ¥566,631,981.31, contrasting with a net decrease of ¥1,422,491,228.84 in the same period last year[62] Shareholder Information - The number of shareholders at the end of the reporting period was 137,549[18] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., held 1,173,237,023 shares, accounting for 46.80% of total shares[18] Government Support and Subsidies - The company received government subsidies amounting to CNY 55,737,931.44 during the reporting period[16] Impairments and Provisions - The company fully recognized impairment provisions for GNC convertible preferred stock investments totaling ¥2,048,661,920, impacting other comprehensive income[25] - The company reported a decrease in other comprehensive income, which worsened from approximately -¥845 million to -¥1.74 billion[39] Future Plans and Strategies - The company plans to actively take measures to reverse the unfavorable situation affecting its financial performance[26] - The company has plans for market expansion and new product development, although specific details were not disclosed in the financial report[35] - The company is focused on expanding its market presence and developing new products and technologies[69]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 4,809,380,177.49, a decrease of 12.81% compared to CNY 5,516,041,838.19 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was a loss of CNY 333,302,234.51, compared to a loss of CNY 42,347,051.96 in the previous year, representing a decline of 687.07%[16]. - The net cash flow from operating activities was a negative CNY 166,711,071.07, showing an improvement of 7.89% from a negative CNY 180,997,503.23 in the same period last year[16]. - The total assets at the end of the reporting period were CNY 10,794,684,609.50, down 13.66% from CNY 12,502,530,832.80 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company decreased to CNY 4,411,221,256.20, a decline of 19.16% compared to CNY 5,456,565,308.41 at the end of the previous year[16]. - Basic earnings per share for the first half of 2020 were -CNY 0.13, a decrease of 550.00% from -CNY 0.02 in the same period last year[17]. - The weighted average return on net assets was -7.56%, a decrease of 6.77 percentage points compared to -0.79% in the previous year[17]. - The company reported a net loss of CNY 1,129,140,214.49 for the first half of 2020, compared to a loss of CNY 663,398,512.00 in the same period of 2019[140]. - The total comprehensive income for the first half of 2020 was a loss of ¥1.01 billion, compared to a loss of ¥1.19 billion in the same period of 2019[145]. Operational Highlights - The company focuses on the pharmaceutical health industry, with 1,806 drug approvals and 83 health product approvals, covering areas such as anti-infection and cardiovascular treatments[21]. - The company expanded its marketing team and increased terminal coverage to enhance market access capabilities in response to the COVID-19 pandemic[27]. - The company has established over 70 production lines for various products, ensuring controlled production processes from raw material intake to finished product delivery[31]. - The company has a strong brand presence with five well-known trademarks and has received multiple awards, enhancing its market competitiveness[28]. - The company has 234 product specifications included in the national medical insurance directory, with a leading market share in certain antibiotic and health supplement categories[28]. - The company actively develops new sales channels and business models to mitigate the impact of the pandemic on physical pharmacy sales[27]. - The company is implementing cost control measures to reduce operational costs through various strategies[34]. - The company plans to enhance product marketing by leveraging high-quality products and expanding brand influence through centralized procurement[38]. Market and Industry Context - In the first half of 2020, the pharmaceutical manufacturing industry saw a revenue of approximately CNY 1,109.4 billion, a year-on-year decrease of 2.3%, while total profit increased by 2.1% to CNY 158.6 billion[26]. - The pharmaceutical manufacturing segment generated 1.301 billion yuan, while the pharmaceutical commercial segment accounted for 3.488 billion yuan[34]. - The company reported a significant increase in revenue from overseas markets, with a growth rate of 123.52% to approximately ¥39.73 million[51]. - The company aims to strengthen its pharmaceutical wholesale business by leveraging upstream resources and enhancing customer management[41]. Environmental and Social Responsibility - The company reported a chemical oxygen demand (COD) discharge concentration of 59.9 mg/L, which is below the permitted limit of 100 mg/L, with a total discharge of 2.29 tons for the first half of 2020[97]. - The ammonia nitrogen discharge concentration was recorded at 1.89 mg/L, significantly lower than the permitted limit of 8 mg/L, with a total discharge of 0.072 tons for the same period[101]. - The company has actively participated in social responsibility initiatives, including donating 125 N95 medical masks to the Yilan County People's Hospital during the pandemic[86]. - The company has reported a total of 100 individuals lifted out of poverty through its targeted poverty alleviation efforts[87]. - The company has established a sustainable industry project in Sixin Village, with an annual income of 280,000 RMB from the cultivation of artificial mushrooms, benefiting each poor household with over 3,000 RMB in dividends[90]. Financial Position and Liabilities - Total assets decreased from RMB 12.50 billion as of December 31, 2019, to RMB 10.79 billion as of June 30, 2020, representing a decline of approximately 13.76%[131]. - Total liabilities decreased from RMB 6.56 billion to RMB 5.89 billion, a decline of about 10.19%[131]. - The company's equity decreased to CNY 2,456,717,534.73 from CNY 3,634,530,038.89, a decline of approximately 32.4%[140]. - The company has recognized an impairment provision of approximately ¥171.41 million for its convertible preferred shares in GNC due to GNC's bankruptcy proceedings[55]. - The company has fully provided for impairment on receivable dividends from GNC, amounting to 171,414,381.09 RMB, which will be reflected in the current period's profit and loss[68]. Future Strategies and Developments - The company plans to focus on market expansion and new product development as part of its future strategy[141]. - The company is exploring potential mergers and acquisitions to enhance its market position and drive future growth[174]. - The company aims to leverage its product resources and brand advantages to strengthen its market position and competitiveness[28]. - The company is actively pursuing the development of generic and innovative drug projects to enrich its product pipeline[38]. Governance and Compliance - The financial statements are prepared based on the going concern principle and comply with the relevant accounting standards[179]. - The company confirms its ability to continue as a going concern for at least 12 months from the reporting date[180]. - The company has not made any changes to its important accounting policies and estimates during the reporting period[183]. - The company engages in various business activities, including drug production, sales, and technology development in the pharmaceutical sector[177].

Financial Performance - In Q1 2020, the company's operating revenue was CNY 2,510,840,032.33, a decrease of 6.11% compared to the same period last year[12]. - The net profit attributable to shareholders was CNY -186,635,649.27, representing a decline of 28.58% year-on-year[12]. - The company faced challenges in sales due to the pandemic, impacting high-margin product sales and overall revenue[12]. - Net profit for Q1 2020 was -174,811,612.15, a decline of 38.23% compared to -126,462,418.82 in Q1 2019, mainly due to decreased sales of high-margin products during the pandemic[21]. - The company reported a total comprehensive loss of ¥329,804,564.61 for Q1 2020, compared to a loss of ¥661,728,834.88 in Q1 2019[46]. - Basic and diluted earnings per share for Q1 2020 were both -¥0.07, compared to -¥0.06 in Q1 2019[46]. Cash Flow - The net cash flow from operating activities improved significantly to CNY -71,626.60, a 99.96% increase compared to the previous year[12]. - Cash flow from operating activities improved significantly, with a net cash flow of -71,626.60 compared to -178,093,682.78 in the previous year, reflecting increased sales collections[21]. - Cash flow from financing activities surged by 824.40% to 303,343,378.15 from 32,814,991.23, mainly due to increased bank loans from subsidiaries[21]. - The net cash flow from operating activities for Q1 2020 was ¥53,487,760.17, a decrease of 56.8% compared to ¥123,752,804.39 in Q1 2019[60]. - Total cash inflow from operating activities was ¥645,157,652.38, down 23% from ¥837,975,928.01 in the same period last year[60]. - Cash outflow from operating activities totaled ¥591,669,892.21, a reduction of 17.2% compared to ¥714,223,123.62 in Q1 2019[60]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 12,372,197,511.26, down 1.04% from the end of the previous year[12]. - Current liabilities increased to ¥6,274,895,125.00, up 3.39% from ¥6,068,590,947.07[32]. - Total liabilities rose to ¥6,759,180,756.72, an increase of 3.05% from ¥6,559,709,513.64[34]. - The company's equity attributable to shareholders decreased to ¥5,114,936,706.67, down 6.24% from ¥5,456,565,308.41[34]. - Total liabilities amounted to approximately ¥6.56 billion, with current liabilities at ¥6.07 billion and non-current liabilities at ¥491.12 million[69]. Shareholder Information - The number of shareholders at the end of the reporting period was 161,125, with the largest shareholder holding 46.80% of the shares[17]. - Shareholders' equity decreased to ¥3,276,742,509.54 in Q1 2020 from ¥3,634,530,038.89 in Q1 2019[40]. - The total equity attributable to shareholders of the parent company is approximately ¥5.46 billion[69]. Income and Expenses - Total operating costs for Q1 2020 were ¥2,716,622,009.04, down 2.4% from ¥2,782,541,653.46 in Q1 2019[43]. - Research and development expenses for Q1 2020 were ¥26,895,395.02, slightly down from ¥27,219,513.99 in Q1 2019[43]. - The company reported a tax expense of ¥21,813,701.94 for Q1 2020, down from ¥37,662,008.79 in Q1 2019[45]. - Selling expenses decreased to approximately ¥6.06 million in Q1 2020, down 47% from ¥11.55 million in Q1 2019[51]. - The company’s financial expenses increased to approximately ¥5.55 million in Q1 2020, compared to ¥2.89 million in Q1 2019[51]. Other Financial Metrics - The weighted average return on equity decreased by 0.91 percentage points to -3.53%[12]. - The company reported a significant increase in cash and cash equivalents, with a 41.80% rise in monetary funds to CNY 957,872,414.27[19]. - Interest expenses increased by 258.18% to 26,230,839.89 from 7,323,343.81 due to higher interest costs from subsidiaries[21]. - Interest income decreased by 60.56% to 2,044,989.09 from 5,184,914.35 primarily due to a reduction in fixed deposits[21]. - The company reported an increase in investment income to approximately ¥38.25 million in Q1 2020, up from ¥26.12 million in Q1 2019[51].

Financial Performance - In 2019, the company reported a net profit of -497,306,797.49 CNY, resulting in a total distributable profit of -663,398,512.00 CNY, leading to no profit distribution or capital reserve increase for the year [6]. - The company's operating revenue for 2019 was CNY 11,824,561,675.04, an increase of 9.35% compared to CNY 10,813,613,594.67 in 2018 [21]. - The net profit attributable to shareholders for 2019 was CNY 55,812,116.14, representing a significant decrease of 83.88% from CNY 346,139,970.93 in 2018 [21]. - The net cash flow from operating activities for 2019 was negative CNY 284,938,535.31, compared to positive CNY 692,724,935.55 in 2018 [21]. - The basic earnings per share for 2019 was CNY 0.02, down 85.71% from CNY 0.14 in 2018 [21]. - The total assets at the end of 2019 were CNY 12,502,530,832.80, an increase of 5.06% from CNY 11,900,901,626.53 at the end of 2018 [21]. - The company reported a net profit of CNY 51,555,047.80 in Q4 2019, following a net loss of CNY 145,155,449.90 in Q1 2019 [24]. - The company recorded non-recurring gains of CNY 67,960,359.17 in 2019, compared to CNY 102,013,850.29 in 2018 [24]. - The weighted average return on equity for 2019 was 0.94%, a decrease of 4.39 percentage points from 5.33% in 2018 [21]. - The gross profit margin for the main business decreased by 3.37 percentage points to 23.73% [40]. - The company achieved a revenue of 11.82 billion RMB, representing a year-on-year growth of 9.35% [36]. - The net profit attributable to shareholders of the listed company was 56 million RMB [36]. Audit and Compliance - The company’s financial report was audited by Beijing Xinghua Accounting Firm, which issued a standard unqualified opinion [5]. - The company has no major litigation or arbitration matters during the reporting period [140]. - The company has maintained a good integrity status with no issues reported for the controlling shareholders or actual controllers [140]. - The company has engaged Beijing Xinghua Accounting Firm for auditing services, with a remuneration of 80 thousand [140]. - The company has not faced any risks of suspension or termination of listing during the reporting period [140]. - The company has implemented new financial instrument standards since January 1, 2019, with adjustments made to financial statement items as per the new regulations [136]. - The adjustments due to the new financial instrument standards affected the consolidated financial statements, with accounts receivable and accounts payable showing significant changes [136]. Market and Industry Position - The company focuses on the pharmaceutical health industry, with a product range including 347 specifications in areas such as anti-infection, cardiovascular, and oncology drugs [28]. - The company’s core products, including penicillin and cephalosporin antibiotics, have a leading market share in their respective segments [31]. - The company has 233 product specifications listed in the 2019 National Medical Insurance Directory, enhancing its market presence [32]. - The pharmaceutical manufacturing industry achieved a revenue of CNY 2,390.86 billion in 2019, with a year-on-year growth of 7.4% [28]. - The company holds a significant position in the domestic antibiotic market, with a product cluster that includes various potential varieties such as fourth-generation cephalosporins and new β-lactam antibiotics [63]. - The company has a strong market share in high-quality chemical preparations, including products like Amoxicillin capsules and Ceftriaxone sodium for injection, particularly in the fields of anti-infection and cardiovascular health [63]. Research and Development - The R&D expenses amounted to CNY 125,142,270.21, a decrease of 8.83% compared to the previous year [40]. - Total R&D investment amounted to 135,430,228.17 yuan, representing 1.15% of operating revenue [52]. - The number of R&D personnel is 224, making up 1.57% of the total workforce [52]. - The company is advancing consistency evaluation work, with 6 products entering the review stage and 32 products progressing in the evaluation process [35]. - The company plans to enhance product consistency evaluation to improve drug access and cost control, aiming for sustainable sales growth [71]. - Research and development efforts have led to two products passing the national consistency evaluation, with ongoing studies for new drug classifications [85]. - The company is committed to improving its research and quality control processes in traditional Chinese medicine to adapt to market developments and regulatory changes [63]. Operational Efficiency and Strategy - The company has implemented a market-oriented management team and restructured its marketing system to improve operational efficiency [31]. - The company is focusing on talent acquisition, optimizing organizational structure, and enhancing management efficiency [35]. - The company is actively managing accounts receivable and inventory to improve cash flow and reduce inventory turnover days [35]. - The company is expanding its e-commerce platform and diversifying sales channels to strengthen market coverage [35]. - The company has refined its customer cooperation and product structure, enhancing sales channel development and brand building [100]. - The company has implemented a sales model combining self-operated teams and specialized distributors, enhancing market coverage and core competitiveness [100]. Environmental Responsibility - The company has established a quality assurance system in line with GMP standards, but still faces quality risks due to uncertainties in raw material procurement and logistics [120]. - The company has installed an online monitoring system for wastewater discharge at three outlets, ensuring compliance with environmental standards [167]. - The company operates two wastewater treatment systems with a combined design capacity of 25,000 tons per day, both functioning normally [167]. - The company has implemented a comprehensive environmental risk emergency mechanism and developed an emergency response plan for sudden environmental pollution incidents [172]. - The company’s environmental management system has been re-certified according to GB/T24001-2016/ISO14001:2015 standards, indicating effective operation [176]. Social Responsibility - The company established the "Harbin Pharmaceutical Public Welfare Foundation" to promote social responsibility and engage in various charitable activities [161]. - The company donated a total of 235,000 RMB in cash and 132,900 RMB in materials for poverty alleviation efforts, benefiting 743 registered impoverished individuals [155]. - The company plans to enhance its support for impoverished households by providing medical assistance and training for agricultural projects, aiming to reduce poverty caused by illness [160]. - The company has actively engaged in social responsibility initiatives, including education support, poverty alleviation, and medical assistance [161]. Shareholder and Capital Structure - The company completed the repurchase and cancellation of 21,561,100 restricted shares on January 15, 2019, and an additional 16,373,100 shares on October 17, 2019 [142][145]. - The controlling shareholder, Harbin Pharmaceutical Group, increased its shareholding ratio from 46.49% to 46.80% [185]. - The total number of ordinary shareholders at the end of the reporting period was 100,241, down from 161,125 at the end of the previous month [185]. - The company’s stock structure post-capital increase includes Harbin State-owned Assets Commission, CITIC Iceland, Huaping Iceland, and others, with the largest shareholder holding 38.25% [197]. - The company has not reported any changes in the actual controller situation during the reporting period [195].

2019 年第三季度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2019 年第三季度报告 1 / 26 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 26 2019 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张镇平、主管会计工作负责人刘波及会计机构负责人（会计主管人员）管平保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|------------------------------------|----- ...

Financial Performance - The company's operating revenue for the first half of 2019 was ¥5,516,041,838.19, a decrease of 2.09% compared to ¥5,633,933,498.80 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was -¥42,347,051.96, compared to a profit of ¥362,976,596.55 in the previous year[21]. - The net cash flow from operating activities was -¥180,997,503.23, a significant decline from ¥93,699,107.55 in the same period last year[21]. - The total assets at the end of the reporting period were ¥11,201,695,633.39, down 5.88% from ¥11,900,901,626.53 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 16.08% to ¥4,922,432,827.33 from ¥5,865,429,231.41 at the end of the previous year[21]. - The basic earnings per share for the first half of 2019 was -¥0.02, compared to ¥0.15 in the same period last year[21]. - The company achieved operating revenue of 5.516 billion yuan, a year-on-year decrease of 2.09%, with pharmaceutical manufacturing revenue at 1.559 billion yuan and pharmaceutical commerce revenue at 3.919 billion yuan, resulting in a net profit attributable to shareholders of -42 million yuan[40]. - The company reported a total comprehensive income of CNY -962,213,754.08 for the first half of 2019, contrasting with CNY 362,976,596.55 in the previous year[159]. - The company reported a significant increase in sales expenses to CNY 388,569,367.10, up from CNY 300,503,762.49, representing a rise of 29.23%[153]. - The company experienced a net loss of CNY 7,960,532.16 for the first half of 2019, compared to a net profit of CNY 398,593,682.96 in the same period of 2018[157]. Operational Highlights - The company completed the repurchase and cancellation of 21,561,100 restricted shares, reducing the total number of shares from 2,544,953,276 to 2,523,392,176[21]. - The company holds 1,816 drug approvals and 77 health product approvals, focusing on therapeutic areas such as anti-infection and cardiovascular diseases[28]. - The company has 356 product specifications currently in production and sales, including key products like Amoxicillin capsules and recombinant human erythropoietin injection[28]. - The company aims to enhance its market presence by expanding its self-operated sales teams and improving channel coverage through partnerships with major pharmaceutical distributors[33]. - The company is actively introducing new products to cultivate new profit growth points and enhance production management capabilities[33]. - The company is focusing on product marketing by enhancing channel coverage through partnerships with major pharmaceutical distribution companies and expanding sales channels, including e-commerce platforms, to tap into county-level and lower-tier city markets[40]. - The company is accelerating product development, with 24 product specifications undergoing consistency evaluation, and has successfully passed the consistency evaluation for montmorillonite powder and four other products are in the review stage[40]. Financial Position - The total liabilities increased from 5,619,979,888.15 to 5,824,592,628.42, an increase of approximately 3.64%[142]. - Total equity decreased from 6,280,921,738.38 to 5,377,103,004.97, a decline of about 14.36%[142]. - The company reported a total current asset of approximately ¥6.25 billion as of June 30, 2019, down from ¥7.20 billion at the end of 2018, representing a decrease of about 13.2%[137]. - The cash and cash equivalents decreased significantly from approximately ¥2.05 billion in December 2018 to approximately ¥619.16 million in June 2019, a decline of about 69.8%[137]. - Accounts receivable increased to approximately ¥3.09 billion as of June 30, 2019, compared to approximately ¥2.52 billion at the end of 2018, reflecting an increase of about 22.7%[137]. - The company reported a significant increase in other receivables, rising from approximately ¥84.22 million in December 2018 to approximately ¥137.50 million in June 2019, an increase of about 63.2%[137]. Risk Management - The company faced no significant risks that could materially affect its operations during the reporting period[6]. - The company anticipates that the pharmaceutical industry will continue to undergo profound changes due to new healthcare policies, which will impact demand structure and competition dynamics[44]. - The company faces industry policy risks due to ongoing medical reforms and structural adjustments in the pharmaceutical sector, which may impact future development[64]. - Environmental protection risks have increased due to stricter regulations, raising challenges in compliance and management[64]. - The company is closely monitoring raw material prices, which are influenced by various factors, and may face procurement cost increases if prices rise significantly[64]. - The company plans to enhance risk control in new product development and strengthen procurement management strategies to mitigate market fluctuations[64]. Community Engagement - The company donated 251,000 RMB to its designated poverty alleviation village, with specific allocations for various community support initiatives[82]. - A total of 743 individuals were helped to escape poverty through the company's targeted poverty alleviation efforts[86]. - The company has implemented a health poverty alleviation initiative, contributing 10,600 RMB to improve medical resources in impoverished areas[87]. - The company aims to host a second community sports event to enrich cultural life and boost morale among villagers, combining poverty alleviation with motivation[89]. Environmental Compliance - The company has established a comprehensive environmental management system and passed ISO14001 certification, ensuring effective operation of pollution control facilities[108]. - The company has installed online monitoring systems for emissions at its facilities, ensuring compliance with environmental standards[94]. - The actual discharge concentration of Chemical Oxygen Demand (COD) for the Harbin Pharmaceutical Group was 67 mg/L, below the permitted limit of 100 mg/L, with a total discharge of 3.91 tons from January to June 2019[98]. - The company is actively implementing pollution prevention measures in response to new environmental regulations, focusing on green, circular, and low-carbon development[105].

证券代码:600664 证券简称:哈药股份 编号:临 2019-032 哈药集团股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 下简称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络 有限公司共同举办的"2019年黑龙江省上市公司投资者网上集体接待 日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互 联 网 平 台 举 行 ， 投 资 者 可 以 登 陆 " 全 景 · 路 演 天 下 " 网 站 （http://rs.p5w.net）参与公司本次投资者集体接待日活动,时间为 2019年6月19日（周三）14:00至16:30。 届时公司董事、副总经理、总会计师刘波先生及董事、副总经理、 董事会秘书孟晓东先生将通过网络在线问答互动的形式，与投资者就 公司治理、发展经营情况、融资情况和可持续发展等投资者关注的问 题进行交流。期间，公司高管将全程在线，实时回答投资者的提问。 ...

Financial Performance - Operating revenue for the first quarter was CNY 2,674,111,617.16, a decrease of 6.43% year-on-year[10] - Net profit attributable to shareholders was a loss of CNY 145,155,449.90, compared to a profit of CNY 140,227,002.06 in the same period last year[10] - The net profit for Q1 2019 was -145,155,449.90 CNY, a significant decline compared to the previous year's profit of 140,227,002.06 CNY, primarily due to a decrease in high-margin product sales[19] - Total revenue for Q1 2019 was ¥2,674,111,617.16, a decrease of 6.4% compared to ¥2,857,831,646.74 in Q1 2018[43] - The total comprehensive income for Q1 2019 was a loss of ¥661,728,834.88, compared to a profit of ¥158,312,018.98 in Q1 2018[46] - The company's operating revenue for Q1 2019 was ¥301,416,101.01, a decrease of 40.4% compared to ¥506,157,126.85 in Q1 2018[47] - The net loss for Q1 2019 was ¥243,211,342.86, compared to a net loss of ¥88,689,214.40 in Q1 2018, indicating a significant decline in profitability[47] Cash Flow and Liquidity - Cash flow from operating activities showed a net outflow of CNY 178,093,682.78, compared to a positive inflow of CNY 142,521,739.09 in the previous year[10] - The net cash flow from operating activities was -178,093,682.78 CNY, a decrease from 142,521,739.09 CNY in the same period last year, attributed to slow cash recovery from the subsidiary[19] - Cash and cash equivalents decreased by 72.51% to CNY 562,947,080.31 due to cash outflow from the subscription of GNC convertible preferred shares[17] - Cash and cash equivalents at the end of Q1 2019 were ¥562,947,080.31, a decrease from ¥3,642,622,394.25 at the end of Q1 2018[54] - The ending balance of cash and cash equivalents decreased to ¥208,242,704.49 in Q1 2019 from ¥2,975,137,374.99 in Q1 2018, indicating a liquidity challenge[59] Assets and Liabilities - Total assets decreased by 4.54% to CNY 11,360,160,858.98 compared to the end of the previous year[10] - Total liabilities increased from 5,619,979,888.15 to 5,717,240,158.43, an increase of about 1.99%[36] - Current liabilities rose from 5,093,281,331.87 to 5,196,850,572.02, reflecting an increase of approximately 2.03%[36] - The company's total assets decreased to ¥8,113,510,599.66 from ¥8,976,044,050.07 year-over-year[43] - Total liabilities decreased to ¥4,268,398,156.62 from ¥4,371,671,198.11 in the previous year[43] - Total non-current assets were approximately $5.03 billion, with fixed assets at approximately $2.09 billion[67] Shareholder Equity - Net assets attributable to shareholders decreased by 11.27% to CNY 5,204,224,715.45 compared to the end of the previous year[10] - Shareholders' equity decreased from 6,280,921,738.38 to 5,642,920,700.55, a decline of about 10.19%[36] - The owner's equity decreased to ¥3,845,112,443.04 from ¥4,604,372,851.96 year-over-year[43] Investment Activities - The company reported a net cash outflow from investing activities of -1,339,583,820.75 CNY, a drastic increase of 15,640.13% compared to -8,510,628.85 CNY in the previous year, mainly due to the subscription of GNC convertible preferred shares[19] - Cash outflow from investing activities in Q1 2019 was ¥1,358,235,466.01, a substantial increase compared to ¥6,965,620.84 in Q1 2018, indicating a shift towards aggressive investment strategies[56] Operational Efficiency - The weighted average return on equity was -2.62%, down from 1.97% in the same period last year[10] - Total operating costs increased to ¥2,809,629,029.03, up 5.7% from ¥2,658,917,387.00 in the previous year[43] - The company reported an operating profit loss of ¥102,176,366.89 compared to an operating profit of ¥207,218,097.76 in Q1 2018[46] - The total operating profit (loss) for Q1 2019 was -¥243,386,906.58, compared to -¥88,699,788.08 in Q1 2018, highlighting a decline in operational efficiency[47] Strategic Initiatives - The company is undergoing a mixed-ownership reform involving its controlling shareholder, which may impact future capital structure and governance[21] - The company is actively taking measures to address the decline in high-margin product sales and aims to reverse the current loss situation[28] - The company is focused on expanding its market presence and developing new technologies to enhance growth prospects[68]

Financial Performance - The company reported a net profit of -268,113,701.56 RMB for the year 2018, resulting in a distributable profit of -199,428,414.51 RMB after accounting for cash dividends of 1,269,734,138.00 RMB[6]. - The company will not distribute profits or increase capital reserves for the year 2018 to ensure stable and sustainable business operations[6]. - The company had an undistributed profit at the beginning of the year amounting to 1,338,419,425.05 RMB[6]. - The company's operating revenue for 2018 was approximately ¥10.81 billion, a decrease of 10.02% compared to ¥12.02 billion in 2017[25]. - Net profit attributable to shareholders was approximately ¥346.14 million, down 14.95% from ¥406.98 million in the previous year[25]. - The net cash flow from operating activities increased significantly to approximately ¥692.72 million, a 364.23% increase from ¥149.22 million in 2017[25]. - The total assets at the end of 2018 were approximately ¥11.90 billion, a decrease of 13.13% from ¥13.70 billion at the end of 2017[25]. - Basic earnings per share for 2018 were ¥0.14, down 12.50% from ¥0.16 in 2017[25]. - The weighted average return on equity for 2018 was 5.33%, a decrease of 0.27 percentage points from 5.60% in 2017[25]. - The company's net assets attributable to shareholders decreased to approximately ¥5.87 billion, down 16.82% from ¥7.05 billion in 2017[25]. Audit and Compliance - The company received a standard unqualified audit report from Beijing Xinghua Accounting Firm[5]. - The company’s financial report is guaranteed to be true, accurate, and complete by its management[4]. - All board members attended the board meeting to review the annual report[5]. - The company has not received any non-standard audit opinions from its accounting firm[150]. - The company has ensured compliance with the new financial and revenue recognition standards as per the Ministry of Finance's regulations[153]. Market and Operational Strategy - The company achieved a total revenue of 2,398.63 billion yuan in the pharmaceutical industry during the reporting period, with a total profit of 309.42 billion yuan[38]. - The company maintains a leading market share in key products such as Amoxicillin capsules and Lisinopril tablets, which are crucial in the anti-infection and cardiovascular treatment sectors[41]. - The company has expanded its distribution network beyond Heilongjiang to Jilin and Inner Mongolia, enhancing its market presence[41]. - The company focuses on optimizing its supply chain and procurement processes to reduce costs and improve efficiency[41]. - The company plans to continue its strategy of industry restructuring, resource optimization, and innovation to enhance market share in niche products[41]. - The company operates a comprehensive marketing network, leveraging its brand advantages to maintain a strong market position in Heilongjiang province[41]. Research and Development - The company has enhanced its research and development capabilities to expand its product offerings and maintain a competitive edge in the market[79]. - The company is actively involved in research and development of new drugs, although specific projects were not detailed in the report[96]. - The company has submitted three generic drug consistency evaluation products for CFDA review, with new drug WX0005 and recombinant human erythropoietin-CTP fusion protein injection preparing for clinical research[108]. - R&D investment totaled CNY 185,300,194.13, representing 1.71% of operating revenue, with 25.92% of R&D costs capitalized[70]. - The company plans to continue focusing on R&D projects in 2019, including key projects under consistency evaluation[115]. Environmental and Social Responsibility - The company has implemented a comprehensive quality assurance system in compliance with national GMP standards, although risks related to product quality remain due to external factors[141]. - The company has established a comprehensive environmental risk emergency mechanism, ensuring rapid and efficient response to pollution incidents[189]. - The company has focused on clean production initiatives, including closed material transport and recovery of volatile organic compounds (VOCs)[192]. - The company has actively participated in social responsibility initiatives, including poverty alleviation and community support programs[172]. - The company donated a total of 62.99 million RMB in funds and 15.07 million RMB in material support for poverty alleviation efforts, helping 95 registered impoverished individuals to escape poverty[176]. Shareholder and Financial Management - The company completed the repurchase and cancellation of 5,485,000 restricted shares on January 10, 2018[197]. - The company has a goal to improve its core competitiveness by enriching its product line and strengthening financial and inventory management in the pharmaceutical wholesale sector[140]. - The company has acknowledged the high risks associated with product R&D, including long cycles and low success rates, and is focusing on risk control in new product development[141]. - The company has implemented various employee engagement activities to enhance workplace culture and employee satisfaction[181]. - The company has committed to avoid any potential competition with its subsidiaries and affiliates[150].

Financial Performance - Total assets decreased by 12.68% to CNY 11,961,635,854.26 compared to the end of the previous year[7] - Net assets attributable to shareholders decreased by 14.47% to CNY 6,031,160,370.62 compared to the end of the previous year[7] - Operating revenue for the first nine months decreased by 12.03% to CNY 8,103,641,395.32 compared to the same period last year[7] - Net profit attributable to shareholders decreased by 7.91% to CNY 242,912,783.90 compared to the same period last year[7] - Basic earnings per share decreased by 9.64% to CNY 0.0956 compared to the same period last year[7] - The company reported a net loss of CNY 35.84 million in the current period compared to a profit of CNY 1.34 billion in the previous period[26] - Total operating revenue for Q3 was approximately $2.47 billion, a decrease of 18.8% compared to $3.04 billion in the same period last year[28] - Net profit for Q3 was a loss of approximately $111.49 million, compared to a loss of $67.51 million in the same quarter last year[29] - The company reported a total comprehensive loss of approximately $111.49 million for Q3, compared to a loss of $67.51 million in the same period last year[30] - The total comprehensive income for the first nine months of 2018 was a loss of approximately ¥104.53 million, compared to a profit of ¥9.00 million in the same period last year[32] Cash Flow and Assets - Net cash flow from operating activities increased by 44.42% to CNY 153,760,407.12 compared to the same period last year[7] - The net cash flow from operating activities for the first nine months of 2018 was ¥153,760,407.12, an increase of 44.42% compared to ¥106,469,128.97 in the same period of 2017[13] - The net cash flow from investing activities was -¥38,364,015.71, a decrease of 67.00% from -¥22,972,809.38 year-on-year, primarily due to increased cash outflows for asset purchases[13] - The net cash flow from financing activities was -¥1,358,709,034.08, an increase of 8.48% compared to -¥1,252,505,379.33, mainly due to the repayment of short-term loans[13] - Total current assets decreased from CNY 5.47 billion to CNY 4.47 billion, a decline of approximately 18.3%[25] - Cash and cash equivalents dropped significantly from CNY 3.03 billion to CNY 1.94 billion, a decline of around 36%[24] - The ending balance of cash and cash equivalents was CNY 1,917,224,112.37, down 38.5% from CNY 3,119,931,639.54 at the end of the same period last year[39] - Cash received from sales of goods and services was CNY 1,081,399,239.69, a decline of 26.0% compared to CNY 1,463,892,353.71 in the same period last year[38] Shareholder Information - The total number of shareholders reached 101,916 by the end of the reporting period[11] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 46.10% of the shares[11] - The company's controlling shareholder, Harbin Pharmaceutical Group, is undergoing mixed-ownership reform, which has not yet resulted in a change of control[13] - The company has not violated any commitments related to its stock reform or major asset restructuring[16][17] Liabilities and Equity - Current liabilities decreased from CNY 5.64 billion to CNY 4.98 billion, a reduction of about 11.7%[22] - Total liabilities decreased from CNY 6.22 billion to CNY 5.53 billion, a decline of approximately 11.1%[22] - Shareholders' equity decreased from CNY 7.48 billion to CNY 6.43 billion, representing a decline of about 14%[22] Expenses - Research and development expenses for Q3 were approximately $22.62 million, a decrease of 39.5% from $37.41 million year-over-year[29] - Sales expenses for Q3 were approximately $157.89 million, down 25% from $210.63 million in the same quarter last year[29] - Research and development expenses for the first nine months of 2018 were approximately ¥59.48 million, down 8.7% from ¥64.73 million in the same period last year[31] - Sales expenses for the first nine months of 2018 were approximately ¥16.19 million, a decrease of 10.4% from ¥18.07 million in the same period last year[31] - The company incurred asset impairment losses of approximately ¥21.09 million in the first nine months of 2018, compared to ¥5.50 million in the same period last year[31] Investment Plans - The company plans to invest in GNC Holdings Inc. by acquiring $300 million in convertible preferred shares, pending regulatory approvals[14]